Difference between revisions of "Part:BBa K4165152"
| Line 8: | Line 8: | ||
ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation. | ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation. | ||
| + | |||
| + | <span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span> | ||
| + | <partinfo>BBa_K4165152 SequenceAndFeatures</partinfo> | ||
===Dry Lab=== | ===Dry Lab=== | ||
| Line 29: | Line 32: | ||
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/isal1-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/isal1-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | ||
</html> | </html> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
===References=== | ===References=== | ||
Revision as of 17:06, 10 October 2022
ISAD1 Peptide
Tau binding peptide targeting the PHF seed of Tau
Usage and Biology
ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Dry Lab
Modeling
ISAD1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest.
Figure 1.: Predicted 3D structure of Synthetic peptide ISAD1.
Table 1: Quality assessment parameters of ISAD1 model.
References
1. Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., ... & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro. Alzheimer's research & therapy, 14(1), 1-19.